18F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer

by Aruz Mesci, Elham Ahmadi, Amr Ali, Mohammad Gouran-Savadkoohi, Evangelia Evelyn Tsakiridis, Olga-Demetra Biziotis, Tom Chow, Anil Kapoor, Monalisa Sur, Gregory R. Steinberg, Stanley Liu, Katherine Zukotynski, Theodoros Tsakiridis
Published 2023-03-01

Combined metformin-salicylate treatment provides improved anti-tumor activity and enhanced radiotherapy response in prostate cancer; drug synergy at clinically relevant doses

by Evangelia E. Tsakiridis, Lindsay Broadfield, Katarina Marcinko, Olga-Demetra Biziotis, Amr Ali, Bassem Mekhaeil, Elham Ahmadi, Kanwaldeep Singh, Aruz Mesci, Panayiotis G. Zacharidis, Alexander E. Anagnostopoulos, Tobias Berg, Paola Muti, Gregory R. Steinberg, Theodoros Tsakiridis
Published 2021-11-01

The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy

by Amr Ali, Bassem Mekhaeil, Olga-Demetra Biziotis, Evangelia E. Tsakiridis, Elham Ahmadi, Jianhan Wu, Simon Wang, Kanwaldeep Singh, Gabe Menjolian, Thomas Farrell, Aruz Mesci, Stanley Liu, Tobias Berg, Jonathan L. Bramson, Gregory R. Steinberg, Theodoros Tsakiridis
Published 2023-09-01

Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α

by Olga‐Demetra Biziotis, Evangelia Evelyn Tsakiridis, Amr Ali, Elham Ahmadi, Jianhan Wu, Simon Wang, Bassem Mekhaeil, Kanwaldeep Singh, Gabe Menjolian, Thomas Farrell, Bassam Abdulkarim, Ranjan K. Sur, Aruz Mesci, Peter Ellis, Tobias Berg, Jonathan L Bramson, Paola Muti, Gregory R Steinberg, Theodoros Tsakiridis
Published 2023-11-01